Alkem Medtech signs pact to acquire 51%-55% stake in Occlutech Holding AG

Alkem Laboratories Ltd 's wholly owned subsidiary, Alkem Medtech Private Limited, has executed a First Supplementary Agreement to advance its acquisition of Occlutech Holding AG. The agreement, signed on June 26, 2026, involves the selling shareholders of the Switzerland-incorporated company. This strategic move aims to secure a controlling interest of at least 51% and up to 55% of the total issued equity share capital of Occlutech.

The transaction follows earlier disclosures made to the stock exchanges on February 13, 2026, and March 6, 2026, which outlined the initial intent to acquire the stake. The execution of the supplementary agreement modifies the original Share Purchase Agreement dated March 6, 2026. The development is part of Alkem Laboratories' broader strategy to expand its footprint through its subsidiary.

Key Transaction Details

The acquisition structure involves Alkem Medtech purchasing shares directly from the existing shareholders of Occlutech. The following table summarizes the key aspects of the agreement:

Aspect	Details
Acquirer	Alkem Medtech Private Limited
Target	Occlutech Holding AG
Stake Acquired	51% to 55% of total issued equity share capital
Target Jurisdiction	Switzerland
Agreement Date	June 26, 2026
Original Agreement	March 6, 2026

The disclosure was submitted to the BSE Limited and the National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer of Alkem Laboratories Limited. A copy of the disclosure has been made available on the company's website.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.16%	-0.77%	+3.57%	-1.73%	+11.18%	+65.03%

Alkem Laboratories has scheduled a virtual meeting with Millennium Management on June 19, 2026, to engage with analysts and institutional investors. The interaction aims to provide insights into the company's operations and strategy. The meeting is part of the company's ongoing investor relations activities under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure was submitted to the stock exchanges, BSE Limited and National Stock Exchange of India Limited, on June 15, 2026. Manish Narang, President – Legal, Company Secretary & Compliance Officer, signed the intimation on behalf of Alkem Laboratories .

Meeting Details

The following table outlines the specifics of the scheduled interaction:

Date	Analyst / Investor	Type of Meeting
June 19, 2026	Millennium Management	Virtual

The company noted that the schedule is subject to change due to unforeseen exigencies on the part of the investor or the company. Alkem Laboratories is headquartered at Alkem House, Senapati Bapat Marg, Lower Parel (West), Mumbai.